Of these, one of the most common is cetuximab, an epidermal growth factor receptor (EGFR) inhibitor that prevents tumor cell proliferation, promotes complement mediated cell lysis, and allows for tumor death via antibody-dependent cell-mediated cytotoxicity. Here, EGFR is linked to neoplasm.